


ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/927,884
				Filing Date	August 10, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1645
				Examiner Name	A. Navarro
				Attorney Docket Number	377882001720
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
~	1.	US-2001/0046967-A1	11-29-2001	Van Nest	
~	2.	US-2002/0055477-A1	05-09-2002	Nest et al.	
~	3.	US-2003/0022852-A1	01-30-2003	Nest et al.	
~	4.	US-2003/0129251-A1	07-10-2003	Van Nest et al.	
~	5.	US-2003/0133988-A1	07-17-2003	Fearon et al.	
~	6.	US-2003/0175731-A1	09-18-2003	Fearon et al.	
~	7.	US-2003/0199466-A1	10-23-2003	Fearon et al.	
~	8.	US-2003/0216340-A1	11-20-2003	Van Nest et al.	
~	9.	US-2005/0037403-A1	02-17-2005	Krieg et al.	
~	10.	US-6,086,901-A	07-11-2000	O'Hagan et al.	
~	11.	US-6,306,405-B1	10-23-2001	O'Hagan et al.	
~	12.	US-6,458,370-B1	10-01-2002	O'Hagan et al.	
~	13.	US-6,534,062-B2	03-18-2003	Raz et al.	
~	14.	US-6,544,518-B1	04-08-2003	Friede et al.	
~	15.	US-6,558,670-B1	05-06-2003	Friede et al.	
~	16.	US-6,610,661-B1	08-26-2003	Carson et al.	
~	17.	US-6,855,492-B2	02-15-2005	O'Hagan et al.	
~	18.	US-6,884,435-B1	04-26-2005	O'Hagan et al.	


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	19.	WO-03/015816-A1	02-27-2003	Dynavax Technologies Corporation		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
~	20.	Aderem, A. et al. (December 22, 2000). "How do you see CG?" <i>Cell</i> 103:993-996.	
~	21.	Gursel, I. et al. (2001). "Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides," <i>J. Immunology</i> 167:3324-3328.	
~	22.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07848 filed March 12, 2001, three pages.	
~	23.	International Search Report mailed on August 27, 2002 for PCT Application No. PCT/US01/25364 filed August 13, 2001, four pages.	
~	24.	International Search Report mailed on February 11, 2002 for PCT Application No. PCT/US01/07843 filed March 12, 2001, three pages.	
~	25.	Kato, D. et al. (2003). "The Design of Polymer Microcarrier Surfaces for Enhanced Cell Growth," <i>Biomaterials</i> 24:4253-4264.	

Examiner Signature	MARK NAVARRO	Date Considered	10/10/06
-----------------------	--------------	--------------------	----------

pa-1058856



ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	09/927,884	
			Filing Date	August 10, 2001	
			First Named Inventor	Gary VAN NEST	
			Art Unit	1645	
			Examiner Name	A. Navarro	
Sheet	2	of	2	Attorney Docket Number	377882001720

~	26.	Kazzaz, J. et al. (2000). "Novel Anionic Microparticles are a Potent Adjuvant for the Induction of Cytotoxic T Lymphocytes Against Recombinant p55 gag From HIV-1," <i>J. Controlled Release</i> 67:347-356.	
~	27.	Klinman, D.M. et al. (2004). "Use of CpG Oligodeoxynucleotides as Immune Adjuvants," <i>Immunological Reviews</i> 199:201-216.	
~	28.	Kofler, N. et al. (1996). "Preparation and Characterization of Poly-(D,L-lactide-co-glycolide) and Poly-(L-lactic acid) Microspheres with Entrapped Pneumotropic Bacterial Antigens," <i>J. Immunological Methods</i> 192:25-35.	
~	29.	Krieg, A.M. (2002). "CpG motifs in Bacterial DNA and Their Immune Effects," <i>Annual Review Immunology</i> 20:709-760.	
~	30.	Lefebvre, D.J. et al. (December 2003). "Th1-directing Adjuvants Increase the Immunogenicity of Oligosaccharide-protein Conjugate Vaccines Related to <i>Streptococcus pneumoniae</i> Type 3," <i>Infection and Immunity</i> 71(12):6915-6920.	
~	31.	Maloy, K.J. et al. (1994). "Induction of Mucosal and Systemic Immune Responses by Immunization with Ovalbumin Entrapped in Poly(lactide-co-glycolide) Microparticles," <i>Immunology</i> 81:661-667.	
~	32.	Nellore, R.V. et al. (September-October 1992). "Evaluation of Biodegradable Microspheres as Vaccine Adjuvant for Hepatitis B Surface Antigen," <i>J. Parenteral Science and Technology</i> 46(5):176-180.	
~	33.	O'Hagan, D.T. et al. (2000). "Microparticles in MF59, a Potent Adjuvant Combination for a Recombinant Protein Vaccine Against HIV-1," <i>Vaccine</i> 18:1793-1801.	
~	34.	O'Hagan, D.T. et al. (2001). "Recent Developments in Adjuvants for Vaccines Against Infectious Diseases," <i>Biomolecular Engineering</i> 18:69-85.	
~	35.	O'Hagan, D.T. et al. (2002). "Synergistic Adjuvant Activity of Immunostimulatory DNA and Oil/water Emulsions for Immunization with HIV p55 gag Antigen," <i>Vaccine</i> 20:3389-3398.	
~	36.	Plenat, F. (June 1996). "Animal Models of Antisense Oligonucleotides: Lessons for use in Humans," <i>Molecular Medicine Today</i> 2(6):250-257.	
~	37.	Ponchel, G. et al. (1998). "Specific and Non-specific Bioadhesive Particulate Systems for Oral Delivery to the Gastrointestinal Tract," <i>Advanced Drug Delivery Reviews</i> 34:191-219.	
~	38.	Ryan, E.J. et al. (August 2001). "Immunomodulators and Delivery Systems for Vaccination by Mucosal Routes," <i>Trends in Biotechnology</i> 19(8):293-304.	
~	39.	Singh, M. et al. (November 1999). "Advances in Vaccine Adjuvants," <i>Nature Biotechnology</i> 17:1075-1081.	
~	40.	Singh, M. et al. (January 18, 2000). "Cationic Microparticles: A Potent Delivery System for DNA Vaccines," <i>PNAS</i> 97(2):811-816.	
~	41.	Uhlmann, E. et al. (2003). "Recent Advances in the Development of Immunostimulatory Oligonucleotides," <i>Current Opinion in Drug Discovery and Development</i> 6(2):204-217.	
~	42.	Weeratna, R.D. et al. (2000). "CpG DNA Induces Stronger Immune Responses with less Toxicity than Other Adjuvants," <i>Vaccine</i> 18:1755-1762.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	MARC NAVARRO	Date Considered	10/10/06
--------------------	--------------	-----------------	----------

pa- 1058856



Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	09/927,884
				Filing Date	August 10, 2001
				First Named Inventor	Gary VAN NEST
				Art Unit	1645
				Examiner Name	A. Navarro
Sheet	1	of	1	Attorney Docket Number	377882001720

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² -Number ³ -Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1.	Du Bois, R.M. (October 21, 1999). "Interferon Gamma-1b for the Treatment of Idiopathic Pulmonary Fibrosis," <i>New England Journal of Medicine</i> 341(17):1302-1304.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	MARK NAVARRO	Date Considered	10/10/06
--------------------	--------------	-----------------	----------